Business
Blau Farmacêutica: Gross margin and EBITDA hit record levels as capacity expansion and pipeline drive future growth
Blau Farmacêutica: Gross margin and EBITDA hit record levels as capacity expansion and pipeline drive future growth
About this update from Blau Farmaceutica Sa
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
View stock analysis, news, and events for Blau Farmaceutica Sa